Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Synairgen (SYNG)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.45 +0.25    +4.03%
13:17:06 - Real-time Data. Currency in GBP ( Disclaimer )
  • Volume: 357,817
  • Bid/Ask: 5.68 / 6.50
  • Day's Range: 5.52 - 6.45
Type:  Equity
Market:  United Kingdom
ISIN:  GB00B0381Z20 
SEDOL:  B0381Z2
Synairgen 6.45 +0.25 +4.03%

Synairgen Company Profile

 
Read the Synairgen company profile to learn more about the business and the management team. View Synairgen facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

24

Equity Type

ORD

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; and IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease. The company was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Contact Information

Address Mailpoint 810 Level F, South Block
Southampton General Hospital Tremona Road Southampton, SO16 6YD
United Kingdom
Phone 44 23 8051 2800
Fax 44 23 8051 2800

Top Executives

Name Age Since Title
Richard Marsden 53 2004 CEO, MD & Executive Director
Simon James Blouet Shaw 56 2003 Non-Executive Chairman
Stephen T. Holgate 73 2003 Co-Founder, Non-Executive Director & Member of Scientific Advisory Board
Donna Davies - - Co-Founder & Member of Scientific Advisory Board
Ratko Djukanovic - - Co-Founder & Member of Scientific Advisory Board
David Bruce Campbell 78 2006 Non-Executive Director & Member of Scientific Advisory Board
Phillip David Monk 54 2009 Chairman of Scientific Advisory Board, Chief Scientific Officer & Executive Director
Amanda Dawn Radford 53 2022 Independent Non-Executive Director
Felicity Jane Gabbay 71 2022 Member of Scientific Advisory Board & Independent Non-Executive Director
Joseph Tregonning Colliver 43 2023 CFO & Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

SYNG Price Commentary

Write your thoughts about Synairgen
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Nicholas Aldam
Nicholas Aldam May 17, 2022 8:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.marketwatch.com/story/synairgen-shares-rise-on-positive-analysis-of-phase-3-covid-19-treatment-trial-271652687610
Sarah Froggatt
Sarah Froggatt May 16, 2022 10:12
Saved. See Saved Items.
This comment has already been saved in your Saved Items
https://www.synairgen.com/media/synairgen-presents-at-ats-2022
Nicholas Aldam
Nicholas Aldam May 16, 2022 8:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Presenting to the ATS today, also rumours for a takeover…
Nicholas Aldam
Nicholas Aldam Apr 26, 2022 8:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Though brief, interesting read and move in the right direction: https://www.synairgen.com/media/presentation-at-eccmid
Elliot dd
Elliot dd Apr 14, 2022 9:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
New promosing drug on the market in the name of VERU. Short Synairgen under 10
Nicholas Aldam
Nicholas Aldam Mar 22, 2022 7:56
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Polygon position, Polygon Global Partners LLP 50,927,428 Ordinary shares (25.3%). Major shareholder, in at different levels, will they sell out, NOPE
Nicholas Aldam
Nicholas Aldam Mar 18, 2022 14:43
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why shouldnt there be a recovery? Polygon still have a major position and speaks volumes, IMO. On unpteen occasions i have said the company are not just covid related researches but also many lung related conditions are u der the microscope. Defo HOLD
Harry Carson
Harry Carson Mar 18, 2022 10:31
Saved. See Saved Items.
This comment has already been saved in your Saved Items
recovery?
Nicholas Aldam
Nicholas Aldam Mar 17, 2022 9:47
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Indeed, oops
Harry Carson
Harry Carson Mar 17, 2022 9:29
Saved. See Saved Items.
This comment has already been saved in your Saved Items
oops
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email